Edwards Lifesciences Corporation (EW) Welcomes Newly Updated ESC/EACTS Guidelines for Severe Aortic Stenosis (AS)

Edwards Lifesciences Corporation (NYSE:EW) is one of the 14 Tech Stocks to Sell Now According to Ken Fisher.

Edwards Lifesciences Corporation (EW) Welcomes Newly Updated ESC/EACTS Guidelines for Severe Aortic Stenosis (AS)

In an announcement on August 29, 2025, Edwards Lifesciences Corporation (NYSE:EW) expressed its positive response to newly updated ESC/EACTS guidelines for severe aortic stenosis (AS), which recommend earlier treatment, including for asymptomatic patients, and lower the TAVR age threshold to 70.

Edwards Lifesciences Corporation (NYSE:EW), as the only company with an approved TAVR indication for asymptomatic severe AS in the U.S. and Europe, highlighted its critical EARLY TAVR trial and the CE Mark for its SAPIEN 3 platform.

Furthermore, Edwards Lifesciences Corporation (NYSE:EW) also presented data from the TRISCEND II study at the same ESC Congress, showing its EVOQUE tricuspid valve replacement significantly reduced heart failure hospitalizations at 18 months. The updated guidelines and clinical evidence strengthen the company’s leadership in structural heart innovation and expand access to transformative therapies.

Edwards Lifesciences Corporation (NYSE:EW) specializes in structural heart therapies, pioneering TAVR, mitral, and tricuspid innovations to improve outcomes and expand access for patients globally. It is one of the stocks to sell.

While we acknowledge the potential of EW to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EW and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 10 Must-Buy Canadian Stocks to Invest in.

Disclosure: None.